{"id":68774,"date":"2026-06-24T00:15:12","date_gmt":"2026-06-23T16:15:12","guid":{"rendered":"https:\/\/flcube.com\/?p=68774"},"modified":"2026-06-24T00:15:13","modified_gmt":"2026-06-23T16:15:13","slug":"abbvie-to-acquire-apogee-therapeutics-for-10-9b-to-expand-inflammatory-disease-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68774","title":{"rendered":"AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>AbbVie Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>) and <strong>Apogee Therapeutics, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/APGE:NASDAQ\">NASDAQ: APGE<\/a>) announced a definitive agreement for AbbVie to acquire Apogee and its diversified pipeline of clinical-stage immunology assets, including promising candidates for <strong>atopic dermatitis (AD)<\/strong> and <strong>asthma<\/strong>, in a transaction valued at approximately <strong>USD 10.9 billion<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-transaction-details\" class=\"wp-block-heading\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>AbbVie Inc. (NYSE: ABBV)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Apogee Therapeutics, Inc. (NASDAQ: APGE)<\/td><\/tr><tr><td><strong>Price per Share<\/strong><\/td><td>USD 135.11 in cash<\/td><\/tr><tr><td><strong>Total Equity Value<\/strong><\/td><td>Approximately USD 10.9 billion<\/td><\/tr><tr><td><strong>Board Approval<\/strong><\/td><td>Unanimously approved by both companies&#8217; boards<\/td><\/tr><tr><td><strong>Expected Closing<\/strong><\/td><td>Third quarter of 2026<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>Expansion of AbbVie&#8217;s immunology franchise beyond Humira<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-apogee-s-core-pipeline-assets\" class=\"wp-block-heading\">Apogee&#8217;s Core Pipeline Assets<\/h2>\n\n\n\n<h3 id=\"h-zumilokibart-apg777\" class=\"wp-block-heading\">Zumilokibart (APG777)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Extended half-life subcutaneous monoclonal antibody targeting <strong>IL-13<\/strong><\/li>\n\n\n\n<li><strong>Indication:<\/strong> Currently in development for <strong>atopic dermatitis (AD)<\/strong><\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Enhanced pharmacokinetic profile enabling less frequent dosing compared to existing IL-13 inhibitors<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-apg273-combination-therapy\" class=\"wp-block-heading\">APG273 Combination Therapy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Composition:<\/strong> Combination of <strong>zumilokibart<\/strong> (anti-IL-13) and <strong>APG333<\/strong> (extended half-life anti-TSLP monoclonal antibody)<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Currently in development for <strong>asthma<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Approach:<\/strong> Dual-pathway inhibition targeting both IL-13 and TSLP pathways for enhanced efficacy in moderate-to-severe asthma<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immunology Leadership:<\/strong> Strengthens AbbVie&#8217;s position as a global leader in immunology following the successful launch of Skyrizi and Rinvoq<\/li>\n\n\n\n<li><strong>Post-Humira Strategy:<\/strong> Represents a key component of AbbVie&#8217;s strategy to diversify revenue streams beyond Humira&#8217;s patent expiry<\/li>\n\n\n\n<li><strong>Pipeline Acceleration:<\/strong> Provides immediate access to late-stage clinical assets with potential for rapid commercial integration<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Addresses high-value segments in atopic dermatitis and asthma markets, which collectively represent multi-billion dollar commercial opportunities<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-impact\" class=\"wp-block-heading\">Financial Impact<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The $10.9 billion acquisition represents a significant but strategic investment for AbbVie, which generated over $50 billion in annual revenue in 2025. The cash transaction will be funded through existing cash reserves and debt financing, maintaining AbbVie&#8217;s investment-grade credit rating. Analysts expect the acquisition to be accretive to earnings within 24 months of closing, assuming successful clinical and regulatory progression.<\/p>\n\n\n\n<h2 id=\"h-competitive-landscape\" class=\"wp-block-heading\">Competitive Landscape<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This acquisition intensifies competition in the immunology space, where AbbVie faces established players like Regeneron, Sanofi, and Novartis in atopic dermatitis, and GSK, AstraZeneca, and Teva in asthma. Apogee&#8217;s differentiated mechanisms of action provide AbbVie with novel therapeutic approaches that could capture market share from existing biologics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding acquisition completion, clinical development, and financial expectations. Actual results may differ materially due to risks including regulatory approvals, antitrust clearances, clinical trial outcomes, and market competition.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie Inc. (NYSE: ABBV) and Apogee Therapeutics, Inc. (NASDAQ: APGE) announced a definitive agreement for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[234,4818,65,4819,853],"class_list":["post-68774","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-abbvie","tag-apogee-therapeutics","tag-auto-immune","tag-nasdaq-apge","tag-nyse-abbv"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AbbVie Inc. (NYSE: ABBV) and Apogee Therapeutics, Inc. (NASDAQ: APGE) announced a definitive agreement for AbbVie to acquire Apogee and its diversified pipeline of clinical-stage immunology assets, including promising candidates for atopic dermatitis (AD) and asthma, in a transaction valued at approximately USD 10.9 billion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68774\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline\" \/>\n<meta property=\"og:description\" content=\"AbbVie Inc. (NYSE: ABBV) and Apogee Therapeutics, Inc. (NASDAQ: APGE) announced a definitive agreement for AbbVie to acquire Apogee and its diversified pipeline of clinical-stage immunology assets, including promising candidates for atopic dermatitis (AD) and asthma, in a transaction valued at approximately USD 10.9 billion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68774\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-23T16:15:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-23T16:15:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68774#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68774\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline\",\"datePublished\":\"2026-06-23T16:15:12+00:00\",\"dateModified\":\"2026-06-23T16:15:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68774\"},\"wordCount\":400,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AbbVie\",\"Apogee Therapeutics\",\"Auto-immune\",\"NASDAQ: APGE\",\"NYSE: ABBV\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68774#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68774\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68774\",\"name\":\"AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-23T16:15:12+00:00\",\"dateModified\":\"2026-06-23T16:15:13+00:00\",\"description\":\"AbbVie Inc. (NYSE: ABBV) and Apogee Therapeutics, Inc. (NASDAQ: APGE) announced a definitive agreement for AbbVie to acquire Apogee and its diversified pipeline of clinical-stage immunology assets, including promising candidates for atopic dermatitis (AD) and asthma, in a transaction valued at approximately USD 10.9 billion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68774#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68774\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68774#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"AbbVie Inc. (NYSE: ABBV) and Apogee Therapeutics, Inc. (NASDAQ: APGE) announced a definitive agreement for AbbVie to acquire Apogee and its diversified pipeline of clinical-stage immunology assets, including promising candidates for atopic dermatitis (AD) and asthma, in a transaction valued at approximately USD 10.9 billion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68774","og_locale":"en_US","og_type":"article","og_title":"AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline","og_description":"AbbVie Inc. (NYSE: ABBV) and Apogee Therapeutics, Inc. (NASDAQ: APGE) announced a definitive agreement for AbbVie to acquire Apogee and its diversified pipeline of clinical-stage immunology assets, including promising candidates for atopic dermatitis (AD) and asthma, in a transaction valued at approximately USD 10.9 billion.","og_url":"https:\/\/flcube.com\/?p=68774","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-23T16:15:12+00:00","article_modified_time":"2026-06-23T16:15:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68774#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68774"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline","datePublished":"2026-06-23T16:15:12+00:00","dateModified":"2026-06-23T16:15:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68774"},"wordCount":400,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AbbVie","Apogee Therapeutics","Auto-immune","NASDAQ: APGE","NYSE: ABBV"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68774#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68774","url":"https:\/\/flcube.com\/?p=68774","name":"AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-23T16:15:12+00:00","dateModified":"2026-06-23T16:15:13+00:00","description":"AbbVie Inc. (NYSE: ABBV) and Apogee Therapeutics, Inc. (NASDAQ: APGE) announced a definitive agreement for AbbVie to acquire Apogee and its diversified pipeline of clinical-stage immunology assets, including promising candidates for atopic dermatitis (AD) and asthma, in a transaction valued at approximately USD 10.9 billion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68774#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68774"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68774#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68774"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68774\/revisions"}],"predecessor-version":[{"id":68775,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68774\/revisions\/68775"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68774"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68774"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}